GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » St Pharm Co Ltd (XKRX:237690) » Definitions » Net Income Including Noncontrolling Interests

St Pharm Co (XKRX:237690) Net Income Including Noncontrolling Interests : ₩27,749 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is St Pharm Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

St Pharm Co's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was ₩709 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was ₩27,749 Mil.

St Pharm Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for St Pharm Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

St Pharm Co Net Income Including Noncontrolling Interests Chart

St Pharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13,154.95 3,377.39 17,515.72 17,523.41 32,463.84

St Pharm Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,423.36 907.08 13,691.84 12,441.57 708.72

St Pharm Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩27,749 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

St Pharm Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of St Pharm Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

St Pharm Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » St Pharm Co Ltd (XKRX:237690) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XKRX:006280 XKRX:069620 XKRX:009420 XKRX:195940 XKRX:185750 XKRX:068760 XKRX:003090 XKRX:086450 XKRX:003850 XKRX:000640 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Teheran Road 78, Gangnam-gu, 7F MSA Building, Daechi-dong, Seoul, KOR, 891-43
Website
http://www.stpharm.co.kr
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm's business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical's business and development of oligonucleotide therapeutics. The company's products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.

St Pharm Co Headlines

No Headlines